WARREN, N.J. (AP) — WARREN, N.J. (AP) — Aquestive Therapeutics Inc. (AQST) on Wednesday reported a loss of $17.1 million in its fourth quarter.
On a per-share basis, the Warren, New Jersey-based company said it had a loss of 19 cents.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The specialty pharmaceutical company posted revenue of $11.9 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $13.5 million.
For the year, the company reported that its loss widened to $44.1 million, or 51 cents per share. Revenue was reported as $57.6 million.
Aquestive Therapeutics expects full-year revenue in the range of $47 million to $56 million.
In the final minutes of trading on Wednesday, the company's shares hit $2.81. A year ago, they were trading at $4.19.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AQST at https://www.zacks.com/ap/AQST
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.